-
Mashup Score: 0Mixed Survival Data for First-Line Combo in Advanced HCC - 2 year(s) ago
In COSMIC-312 interim analysis, cabozantinib plus atezolizumab hits PFS endpoint, misses on OS
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 1Quantifying the burden of rare cancers in Asia - 2 year(s) ago
Epidemiological data may stimulate national cancer control programmes, pharmaceutical company interest and clinical trial participation
Source: Daily ReporterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ESMOasiaweek21: How can quantifying the burden of #rarecancers in Asia improve pts outcomes? National #cancer control programmes, pharmaceutical company interest & facilitation of clinical trial participation may be stimulated by epidemiological data 👉 https://t.co/yHMiN1Dgzn https://t.co/ZjvjbWtn4F
-
-
Mashup Score: 0Do biosimilars improve access to oncology medicines in Asia? - 2 year(s) ago
Biosimilars make certain medicines more affordable, but cost and availability drive the need to find ways to improve access
Source: Daily ReporterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0ESMO Webinar on Gastric Cancer - 2 year(s) ago
This ESMO Webinar is part of the ESMO Asia Virtual Oncology Week 2021, which is freely available to all healthcare professionals working in Oncology.
Source: www.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1ESMO Webinar on Gastric Cancer - 2 year(s) ago
This ESMO Webinar is part of the ESMO Asia Virtual Oncology Week 2021, which is freely available to all healthcare professionals working in Oncology.
Source: www.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Practice-changing results in breast cancer in LMIC - 2 year(s) ago
Cost, limited drug availability and lack of diagnostic testing facilities are hurdles to adopting practice-changing recommendations in Asia
Source: Daily ReporterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Impact of first-line nivolumab on subsequent therapy choices - 2 year(s) ago
In gastric cancer, effects of early immune checkpoint inhibitor use stimulate consideration of alternative approaches for further treatment lines
Source: Daily ReporterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Module - 2 year(s) agoSource: asiaweek.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0The management of head and neck cancer in Asia - 2 year(s) ago
The Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines is presented at the ESMO Asia Virtual Oncology Week 2021
Source: Daily ReporterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Should renal cell carcinomas be managed differently in Asia? - 2 year(s) ago
The Pan-Asian adaptation of the ESMO guidelines are presented at the ESMO Asia Oncology Week 2021
Source: Daily ReporterCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ESMOasiaweek21: Should #renalcellcarcinomas be managed differently in Asia? The Pan-Asian Adaptation of the ESMO Guidelines introduces some changes, including diagnostic tests and the use of cytoreductive nephrectomy. https://t.co/l5ZbfxBB1Z #kcsm #KidneyCancer @ravikanesvaran https://t.co/60Ij0gC82W
-
Cabometyx plus Tecentriq significantly improved progression-free survival versus Nexavar alone for these patients, reported Robin Kate Kelley, MD. @myESMO #ESMOasiaweek21 https://t.co/LEPxyFbgiZ